Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Sellers Covered 12.08% of Their Shorts

September 17, 2017 - By Adrian Mccoy

 Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Sellers Covered 12.08% of Their Shorts

The stock of Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) registered a decrease of 12.08% in short interest. CATB’s total short interest was 712,500 shares in September as published by FINRA. Its down 12.08% from 810,400 shares, reported previously. With 190,400 shares average volume, it will take short sellers 4 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Incorporated’s float is 6.81%.

The stock increased 0.60% or $0.01 on September 15, reaching $1.69. About 943,837 shares traded or 137.46% up from the average. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 73.74% since September 17, 2016 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $37.99 million. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted , a linker drug discovery platform. It currently has negative earnings. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 10 analyst reports since August 17, 2015 according to SRatingsIntel. Citigroup maintained the stock with “Buy” rating in Tuesday, March 22 report. The firm earned “Buy” rating on Monday, August 14 by Wedbush. The rating was maintained by Cowen & Co on Thursday, August 10 with “Hold”. The firm has “Buy” rating by Citigroup given on Thursday, June 9. On Thursday, December 22 the stock rating was initiated by H.C. Wainwright with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $9.2900 target in Monday, August 14 report. On Wednesday, June 8 the stock rating was maintained by Wedbush with “Outperform”. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) earned “Buy” rating by Oppenheimer on Monday, August 14. As per Monday, August 17, the company rating was maintained by Wedbush.

More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: Marketwatch.com which released: “Catabasis Pharma surges 17% on positive early-stage clinical trial results for …” on January 19, 2017, also Businesswire.com with their article: “Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference” published on June 23, 2017, Seekingalpha.com published: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q1 2017 Results – Earnings …” on May 12, 2017. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: Businesswire.com and their article: “Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late …” published on September 14, 2017 as well as Businesswire.com‘s news article titled: “Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD” with publication date: January 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.